Comparison of adverse events during capecitabine versus 5-fluorouracil/oxaliplatin adjuvantchemotherapy for stage II/III colon cancer: A population based analysis.

被引：0
|
作者：
Pabani, Aliyah
Mazurek, Matthew
Cheung, Winson Y.
Spratlin, Jennifer L.
Hiller, Julie A. Price
Standeven, Leah Jean
Mulder, Karen E.
Ghosh, Sunita
Ho, Maria Yi
机构：
[1] Univ Alberta, Edmonton, AB, Canada
[2] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[3] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[4] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e14663
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14663
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX)
    Kim, Jeong Eun
    Hong, Yong Sang
    Kim, Hwa Jung
    Kim, Kyu-pyo
    Kim, Sun Young
    Lim, Seok-Byung
    Park, In Ja
    Kim, Chan Wook
    Yoon, Yong Sik
    Yu, Chang Sik
    Kim, Jin Cheon
    Kim, Ji Hun
    Kim, Tae Won
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (05) : 1289 - 1294
  • [32] Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
    Buchler, Tomas
    Pavlik, Tomas
    Melichar, Bohuslav
    Bortlicek, Zbynek
    Usiakova, Zuzana
    Dusek, Ladislav
    Kiss, Igor
    Kohoutek, Milan
    Benesova, Vera
    Vyzula, Rostislav
    Abrahamova, Jitka
    Obermannova, Radka
    BMC CANCER, 2014, 14
  • [33] Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial
    Feng, Yan-Ru
    Zhu, Yuan
    Liu, Lu-Ying
    Wang, Wei-Hu
    Wang, Shu-Lian
    Song, Yong-Wen
    Wang, Xin
    Tang, Yuan
    Liu, Yue-Ping
    Ren, Hua
    Fang, Hui
    Zhang, Shi-Ping
    Liu, Xin-Fan
    Yu, Zi-Hao
    Li, Ye-Xiong
    Jin, Jing
    ONCOTARGET, 2016, 7 (18) : 25576 - 25584
  • [34] Comparison between oxaliplatin therapy and capecitabine monotherapy for high-risk stage II-III elderly patients with colon cancer
    Park, Jueun
    Baik, HyungJoo
    Kang, Sang Hyun
    Seo, Sang Hyuk
    Kim, Kwang Hee
    Oh, Min Kyung
    Lee, Hong Sub
    Lee, Sang Heon
    Kim, Ki Hyang
    An, Min Sung
    ASIAN JOURNAL OF SURGERY, 2022, 45 (01) : 448 - 455
  • [35] PHARMACOECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS 5-FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE FIRST LINE TREATMENT OF METASTASIS COLORECTAL CANCER IN TAIWAN
    Chen, H. H.
    Chang, C. S.
    Chen, L. T.
    Chen, W. T.
    Hsu, T. C.
    Wang, J. Y.
    Wen, C. Y.
    VALUE IN HEALTH, 2009, 12 (07) : A278 - A278
  • [36] A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
    W Schippinger
    H Samonigg
    R Schaberl-Moser
    R Greil
    R Thödtmann
    J Tschmelitsch
    M Jagoditsch
    G G Steger
    R Jakesz
    F Herbst
    F Hofbauer
    H Rabl
    P Wohlmuth
    M Gnant
    J Thaler
    British Journal of Cancer, 2007, 97 : 1021 - 1027
  • [37] A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
    Schippinger, W.
    Samonigg, H.
    Schaberl-Moser, R.
    Greil, R.
    Thoedtmann, R.
    Tschmelitsch, J.
    Jagoditsch, M.
    Steger, G. G.
    Jakesz, R.
    Herbst, F.
    Hofbauer, F.
    Rabl, H.
    Wohlmuth, P.
    Gnant, M.
    Thaler, J.
    BRITISH JOURNAL OF CANCER, 2007, 97 (08) : 1021 - 1027
  • [38] Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data
    Amlani, Adam
    Kumar, Aalok
    Ruan, Jenny Y.
    Cheung, Winson Y.
    CANCER MEDICINE, 2016, 5 (08): : 1776 - 1782
  • [39] Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis.
    Arkenau, HT
    Schmoll, H
    Kubicka, S
    Seufferlein, T
    Reichardt, P
    Freier, W
    Graeven, U
    Grothey, A
    Porschen, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 256S - 256S
  • [40] Cost-minimisation analysis of rectal cancer neoadjuvant chemoradiotherapy based on fluoropyrimidines (capecitabine versus 5-fluorouracil)
    Marin, Sergio
    Perez-Cordon, Laia
    Salva, Francesc
    la Camps, Marcel
    Campins, Lluis
    Lianes, Pilar
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (E1) : E13 - E17
12345